Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis

被引：0
|
作者：
Fu, S. [1 ]
Liu, J. [1 ]
Fu, P. [2 ]
Li, H. [3 ]
Yang, X. [3 ]
Xie, C. [1 ]
Zhang, J. [1 ]
机构：
[1] Shandong Univ, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[2] Jinan Zhangqiu Dist Peoples Hosp, Jinan, Peoples R China
[3] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
EGFR mutant NSCLC; Brain Metastasis; Aumolertinib combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-03
引用
收藏
页码：S414 / S415
页数：2
相关论文
共 50 条
  • [1] First-Line Icotinib Versus Cisplatine/Pemetrexed Plus Pemetrexed Maintenance in Advanced NSCLC Patients with EGFR Mutation
    Shi, Yuankai
    Wang, Lin
    Han, Baohui
    Li, Wei
    Yu, Ping
    Liu, Yunpeng
    Ding, Cuimin
    Song, Xia
    Ma, Zhiyong
    Ren, Xinling
    Feng, Jifeng
    Zhang, Helong
    Chen, Gongyan
    Wu, Ning
    Han, Xiaohong
    Yao, Chen
    Song, Yong
    Zhang, Shucai
    Ding, Lieming
    Tan, Fenlai
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S205 - S206
  • [2] Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)
    Goto, Y.
    Takahashi, K.
    Saito, H.
    Ogasawara, T.
    Shindoh, J.
    Kimura, T.
    Sugino, Y.
    Kojima, E.
    Nomura, F.
    Nakanishi, T.
    Nozaki, Y.
    Takeyama, Y.
    Imaizumi, K.
    Hasegawa, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S469 - S470
  • [3] Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment
    Wu, Q.
    Li, W.
    Wang, J. T.
    Pu, D.
    Li, Y.
    Xu, F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S664 - S664
  • [4] Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib
    Duan, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S652
  • [5] Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients
    Zhang, H.
    Cun, F. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1587
  • [6] Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR plus NSCLC Patients: The Updated Results
    Fang, S.
    Xu, T.
    Zhao, X.
    Liu, N.
    Wang, X.
    Cheng, W.
    Fang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S671
  • [7] High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
    Fan, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S422 - S422
  • [8] A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis
    Fang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S422 - S422
  • [9] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): A randomized multicenter study
    Hu, Y.
    Zhang, F.
    Zhao, M.
    Zheng, Z.
    Zhang, H.
    Jiang, T.
    Liu, Z.
    Wen, J.
    Gan, X.
    Wang, H.
    Wu, L.
    Cang, S.
    Zhao, J.
    Li, X.
    Peng, L.
    Fan, Z.
    Shen, G.
    Zhou, Q.
    Zou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1312 - S1312
  • [10] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Zhang, Fan
    Hu, Yi
    Han, Xiao
    Hu, ZhiSong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345